PMID- 36342252
OWN - NLM
STAT- MEDLINE
DCOM- 20221110
LR  - 20221222
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 48
IP  - 11
DP  - 2022 Nov 1
TI  - Prospective Study of 532-nm Picosecond Laser for the Treatment of Pigmented 
      Lesions of the Face and Dorsal Hands.
PG  - 1215-1219
LID - 10.1097/DSS.0000000000003602 [doi]
AB  - BACKGROUND: Pigmented lesions from chronic UV photoaging are extremely common on 
      the face and hands. OBJECTIVE: To evaluate the safety and efficacy of a 532-nm 
      picosecond laser for these types of pigmented lesions. METHODS: This was a 
      single-center, prospective, open-label clinical trial. Eligible subjects with 
      pigmentation on the face and hands received 3 monthly treatments, with 1 month 
      (1M) and 3 months (3M) follow-up. Change in investigator-graded overall facial 
      and per lesion pigmentation and subject-graded satisfaction and pigmentation 
      improvement was evaluated by a 5-point scale. Immediate skin response and adverse 
      events (AEs) were evaluated post-treatment. The melanin index was measured using 
      a mexameter. Randomized before and after photographs were graded by 3 blinded 
      physicians for degree of pigmentation improvement. RESULTS: Twenty-five subjects 
      (22F/3M) with Fitzpatrick skin types I-III were enrolled, with 23 subjects 
      completing. Treatments used a 532 nm wavelength, 800 ps pulse duration, 4-6mm 
      spot size, and 0.1 to 0.6J/cm2 fluence. Good-to-excellent clearance at 1M/3M was 
      demonstrated in >/=95% of lesions (n = 116). Only mild treatment-related pain was 
      reported, with transient post-treatment AEs (mean downtime of 2.1 +/- 2.0 days) and 
      no serious treatment-related AEs. Subject satisfaction (satisfied or very 
      satisfied) was 95% at 1M and 91% at 3M. CONCLUSION: Treatment with a 532-nm 
      picosecond laser is safe and highly effective for the treatment of the pigmented 
      lesions of the face and dorsal hands.
CI  - Copyright (c) 2022 by the American Society for Dermatologic Surgery, Inc. Published 
      by Wolters Kluwer Health, Inc. All rights reserved.
FAU - Friedmann, Daniel P
AU  - Friedmann DP
AD  - Westlake Dermatology Clinical Research Center, Westlake Dermatology and Cosmetic 
      Surgery, Austin, Texas.
FAU - Timmerman, Alina
AU  - Timmerman A
AD  - Lumenis Ltd, Yokneam, Israel.
FAU - Cahana, Zoya
AU  - Cahana Z
AD  - Lumenis Ltd, Yokneam, Israel.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20221018
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
SB  - IM
MH  - Humans
MH  - *Lasers, Solid-State/adverse effects
MH  - *Low-Level Light Therapy/adverse effects
MH  - *Pigmentation Disorders/radiotherapy
MH  - Prospective Studies
MH  - *Skin Aging
MH  - Treatment Outcome
MH  - Male
MH  - Female
EDAT- 2022/11/08 06:00
MHDA- 2022/11/09 06:00
CRDT- 2022/11/07 08:43
PHST- 2022/11/07 08:43 [entrez]
PHST- 2022/11/08 06:00 [pubmed]
PHST- 2022/11/09 06:00 [medline]
AID - 00042728-202211000-00016 [pii]
AID - 10.1097/DSS.0000000000003602 [doi]
PST - ppublish
SO  - Dermatol Surg. 2022 Nov 1;48(11):1215-1219. doi: 10.1097/DSS.0000000000003602. 
      Epub 2022 Oct 18.